RxDoctor Payments Data

Elizabeth Kozlowski, DO

Family Medicine · East Lansing, MINPI 1104804285

Payments from drug & device makers

$7,113in general payments, 2019–2025

Across 403 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$869
  • AstraZeneca$706
  • Pfizer$544
  • Lilly USA, LLC$229
  • Takeda Pharmaceuticals U.S.A., Inc.$208
  • plus $3K from 52 others
$150in research payments, 2019–2025

Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$150

What the payments were for

  • Food & beverage$7,03999%
  • Education$741%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,113 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$30,052
Medicare patients
52
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide97$118,974
MounjaroTirzepatide34$35,281
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$26,401
TrulicityDulaglutide16$20,922
XyostedTestosterone Enanthate22$16,184
VraylarCariprazine Hcl12$15,355
MyrbetriqMirabegron12$9,561
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl30$7,035
EstringEstradiol14$6,929
Novolog FlexpenInsulin Aspart13$2,137
Levothyroxine Sodium179$2,081
Estradiol34$1,875
Rosuvastatin Calcium69$1,476
Celecoxib47$1,232
Pregabalin33$1,166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,754$118,97497 claims
Lilly USA, LLCMounjaro, Trulicity$229$56,20450 claims
GSKTrelegy Ellipta$97$26,40125 claims
Antares Pharma, Inc.Xyosted$49$16,18422 claims
AbbVieVraylar, Synthroid$869$16,18123 claims
Astellas Pharma US IncMyrbetriq$22$9,56112 claims
PfizerEstring$544$6,92914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in East Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →